Clarus Wealth Advisors Takes Position in Pfizer Inc. (NYSE:PFE)

view original post

Clarus Wealth Advisors purchased a new stake in shares of Pfizer Inc. (NYSE:PFEGet Rating) in the 1st quarter, Holdings Channel reports. The fund purchased 3,732 shares of the biopharmaceutical company’s stock, valued at approximately $201,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in PFE. Norges Bank purchased a new stake in shares of Pfizer during the 4th quarter valued at about $3,351,891,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its stake in shares of Pfizer by 577.8% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 12,247,903 shares of the biopharmaceutical company’s stock valued at $715,270,000 after acquiring an additional 10,440,786 shares during the period. Coatue Management LLC bought a new position in shares of Pfizer during the 4th quarter valued at approximately $608,919,000. Darwin Global Management Ltd. bought a new position in shares of Pfizer during the 4th quarter valued at approximately $454,553,000. Finally, State Street Corp grew its stake in shares of Pfizer by 1.8% during the 4th quarter. State Street Corp now owns 284,816,832 shares of the biopharmaceutical company’s stock valued at $16,818,434,000 after acquiring an additional 5,013,651 shares during the period. 66.50% of the stock is owned by hedge funds and other institutional investors.

NYSE PFE opened at $49.07 on Thursday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.13 and a current ratio of 1.39. The company has a market capitalization of $275.33 billion, a P/E ratio of 11.25, a P/E/G ratio of 0.56 and a beta of 0.76. Pfizer Inc. has a one year low of $38.82 and a one year high of $61.71. The stock has a 50 day moving average price of $50.57 and a 200-day moving average price of $52.22.

Pfizer (NYSE:PFEGet Rating) last released its quarterly earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 earnings per share for the quarter, missing the consensus estimate of $1.66 by ($0.04). Pfizer had a net margin of 26.97% and a return on equity of 38.29%. The company had revenue of $25.66 billion for the quarter, compared to analysts’ expectations of $24.73 billion. During the same quarter in the previous year, the company posted $0.93 EPS. The business’s quarterly revenue was up 76.8% on a year-over-year basis. As a group, equities analysts predict that Pfizer Inc. will post 6.61 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Friday, June 10th. Investors of record on Friday, May 13th were issued a dividend of $0.40 per share. The ex-dividend date of this dividend was Thursday, May 12th. This represents a $1.60 annualized dividend and a yield of 3.26%. Pfizer’s payout ratio is presently 36.70%.

In other Pfizer news, EVP William R. Carapezzi, Jr. sold 32,908 shares of the stock in a transaction on Thursday, May 12th. The stock was sold at an average price of $50.00, for a total value of $1,645,400.00. Following the sale, the executive vice president now owns 38,146 shares in the company, valued at $1,907,300. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Jennifer B. Damico sold 4,218 shares of the stock in a transaction on Tuesday, June 7th. The stock was sold at an average price of $53.96, for a total value of $227,603.28. Following the completion of the sale, the senior vice president now owns 10,846 shares in the company, valued at approximately $585,250.16. The disclosure for this sale can be found here. Insiders have sold a total of 41,126 shares of company stock worth $2,075,003 in the last 90 days. 0.05% of the stock is currently owned by insiders.

A number of brokerages recently issued reports on PFE. SVB Leerink began coverage on Pfizer in a research note on Monday, May 23rd. They set a “market perform” rating and a $55.00 price objective for the company. Morgan Stanley assumed coverage on Pfizer in a research note on Wednesday, April 6th. They set an “equal weight” rating and a $55.00 price objective for the company. StockNews.com upgraded Pfizer from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, April 19th. Barclays set a $52.00 price target on Pfizer in a research note on Tuesday, May 17th. Finally, Berenberg Bank set a $50.00 price target on Pfizer in a research note on Friday, May 27th. Nine analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $57.26.

Pfizer Profile (Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Recommended Stories

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEGet Rating).

Receive News & Ratings for Pfizer Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts